These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
214 related items for PubMed ID: 19382270
1. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. J Med Virol; 2009 Jun; 81(6):1032-9. PubMed ID: 19382270 [Abstract] [Full Text] [Related]
2. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Kobayashi M, Arase Y, Ikeda K, Kumada H. J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715 [Abstract] [Full Text] [Related]
3. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. J Med Virol; 2011 Jun; 83(6):1016-22. PubMed ID: 21503914 [Abstract] [Full Text] [Related]
4. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis. Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. J Med Virol; 2005 Apr; 75(4):550-8. PubMed ID: 15714492 [Abstract] [Full Text] [Related]
5. Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment. Ogura S, Akuta N, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Kobayashi M, Suzuki F, Suzuki Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Intervirology; 2009 Apr; 52(4):179-88. PubMed ID: 19546575 [Abstract] [Full Text] [Related]
6. Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy. Seko Y, Akuta N, Suzuki F, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Intervirology; 2013 Apr; 56(1):13-21. PubMed ID: 22907167 [Abstract] [Full Text] [Related]
7. Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. Kobayashi M, Akuta N, Suzuki F, Hosaka T, Sezaki H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Mineta R, Iwasaki S, Miyakawa Y, Kumada H. J Med Virol; 2010 Jan; 82(1):41-8. PubMed ID: 19950230 [Abstract] [Full Text] [Related]
8. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610 [Abstract] [Full Text] [Related]
9. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C. Tachi Y, Katano Y, Honda T, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Nakano I, Samejima Y, Goto H. Liver Int; 2010 Apr; 30(4):554-9. PubMed ID: 19951380 [Abstract] [Full Text] [Related]
10. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448 [Abstract] [Full Text] [Related]
11. Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. J Med Virol; 2008 Aug; 80(8):1354-62. PubMed ID: 18551609 [Abstract] [Full Text] [Related]
12. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035 [Abstract] [Full Text] [Related]
13. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. Poustchi H, Negro F, Hui J, Cua IH, Brandt LR, Kench JG, George J. J Hepatol; 2008 Jan; 48(1):28-34. PubMed ID: 17977612 [Abstract] [Full Text] [Related]
14. Management strategies using pharmacogenomics in patients with severe HCV-1b infection: a decision analysis. Moriguchi H, Uemura T, Kobayashi M, Chung RT, Sato C. Hepatology; 2002 Jul; 36(1):177-85. PubMed ID: 12085363 [Abstract] [Full Text] [Related]
15. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. Hepatology; 2007 Nov; 46(5):1357-64. PubMed ID: 17657816 [Abstract] [Full Text] [Related]
16. Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin. Inoue Y, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Fukuda K, Mita E, Haruna Y, Inoue A, Imai Y, Hosui A, Miyagi T, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. J Med Virol; 2011 Mar; 83(3):419-27. PubMed ID: 21264862 [Abstract] [Full Text] [Related]
17. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. Petta S, Cammà C, Di Marco V, Cabibi D, Ciminnisi S, Caldarella R, Licata A, Massenti MF, Marchesini G, Craxì A. Antivir Ther; 2009 Mar; 14(5):631-9. PubMed ID: 19704165 [Abstract] [Full Text] [Related]
18. Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. J Med Virol; 2010 Apr; 82(4):575-82. PubMed ID: 20166188 [Abstract] [Full Text] [Related]
19. A nucleotide sequence variation detection system for the core region of hepatitis C virus-1b. Okamoto K, Akuta N, Kumada H, Kobayashi M, Matsuo Y, Tazawa H. J Virol Methods; 2007 Apr; 141(1):1-6. PubMed ID: 17184852 [Abstract] [Full Text] [Related]
20. Assessment of specific antibodies to F protein in serum samples from Chinese hepatitis C patients treated with interferon plus ribavarin. Gao DY, Zhang XX, Hou G, Jin GD, Deng Q, Kong XF, Zhang DH, Ling Y, Yu DM, Gong QM, Zhan Q, Yao BL, Lu ZM. J Clin Microbiol; 2008 Nov; 46(11):3746-51. PubMed ID: 18832124 [Abstract] [Full Text] [Related] Page: [Next] [New Search]